燃石医学 Burning Rock Biotech

燃石医学 Burning Rock Biotech company information, Employees & Contact Information

About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of: 1) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively. 2) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology. 燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖: 1)基于NGS的肿瘤患病人群检测,累计检测样本超过27万例,在中国拥有领先的市场份额; 2)基于NGS的癌症早检,目前已经进入临床验证阶段。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊断领域具有里程碑式意义。位于中国广州的实验室通过广东省临检中心颁发的“高通量测序实验室”技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。

Company Details

Employees
184
Founded
-
Address
国际生物岛螺旋四路7号标准产业单元二期3栋, 广州,海珠区 510300,china
Phone
020-34037872
Email
in****@****ech.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
广州, 海珠区
Looking for a particular 燃石医学 Burning Rock Biotech employee's phone or email?

燃石医学 Burning Rock Biotech Questions

News

Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer - taiwannews.com.tw

Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer taiwannews.com.tw

Burning Rock Reports Second Quarter 2025 Financial Results - GlobeNewswire

Burning Rock Reports Second Quarter 2025 Financial Results GlobeNewswire

Major Breast Cancer Diagnostic Breakthrough: Burning Rock's OncoScreen Plus CDx System Gets Japan Green Light - Stock Titan

Major Breast Cancer Diagnostic Breakthrough: Burning Rock's OncoScreen Plus CDx System Gets Japan Green Light Stock Titan

Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers - Wiley

Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers Wiley

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024 - GlobeNewswire

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024 GlobeNewswire

Burning Rock Announces Pricing of Initial Public Offering - GlobeNewswire

Burning Rock Announces Pricing of Initial Public Offering GlobeNewswire

Top 燃石医学 Burning Rock Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant